Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 12, 2017
Pharmacy Choice - News - Drug Delivery Systems - December 12, 2017

Pharmacy News

 Drug Delivery Systems
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 131     Next >>     Go To Page:

12/12/17 - Alembic Pharma gains on USFDA approval for Darifenacin [India Infoline News Service]
Alembic Pharmaceuticals Limited today announced that the company has received approval from the US Food and Drug Administration for its Abbreviated New Drug Application Darifenacin Extended- Release Tablets, 7.5 mg and 15 mg. Alembic Pharmaceuticals, a leading pharmaceutical company, is a market leader in the macrolides segment of anti-infective dr
12/12/17 - Corium to Join NASDAQ Biotechnology Index
Corium International, Inc., a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that it has been selected for addition to the NASDAQ Biotechnology Index as part of the NBI s annual re-ranking, which will become effective prior to market op
12/12/17 - Determination That NOROXIN (Norfloxacin) Tablets, 400 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
This determination will allow FDA to approve abbreviated new drug applications for norfloxacin tablets, 400 mg, if all other legal and regulatory requirements are met. The 1984 amendments include what is now section 505 of the Federal Food, Drug, and Cosmetic Act, which requires FDA to publish a list of all approved drugs. Under FDA regulations, dr
12/12/17 - Findings from Z. Sun and Co-Researchers Advance Knowledge in Drug Delivery Systems (Matrix Metalloproteinase Cleavable Nanoparticles for Tumor...
By a News Reporter-Staff News Editor at Cancer Weekly Investigators publish new report on Drugs and Therapies- Drug Delivery Systems. According to news reporting originating in Shanghai, People's Republic of China, by NewsRx journalists, research stated, "Matrix metalloproteinases, mostly abundant in the tumor extracellular matrix, tumor cells, a
12/12/17 - Global Drug Device Combination Products Market: Segmental Highlights and Table of Content (2013 2019): Global Market for Drug Device Combination Products to be driven by Growing Demand for Minimally Invasive Surgical Procedures
Albany, NY 12/11/2017 According to the research study, in 2012, the global drug device combination products market was worth US $66 bn and is anticipated to reach US $115 bn by the end of 2019, exhibiting a 7.9% CAGR between 2013 and 2019. The research report has made use of graphics, tables, and charts to present the historical data as well
12/12/17 - Impax Receives Tentative FDA Approval of Generic Coreg CR Extended-Release Capsules
BRIDGEWATER, N.J.- Impax Laboratories, Inc., a specialty pharmaceutical company, today announced it has received tentative U.S. Food and Drug Administration approval on its Abbreviated New Drug Application for a generic version of Coreg CR extended-release capsules, 10, 20, 40 and 80 mg. Impax Laboratories, Inc. is a specialty pharmaceutical compan
12/12/17 - Indivior Announces NDA Acceptance of RBP-7000 Risperidone Monthly Depot
SLOUGH, England and RICHMOND, Va., Dec. 12, 2017/ PRNewswire/ Indivior PLC today announces that the U.S. Food and Drug Administration has accepted the New Drug Application for RBP-7000, an investigational, once-monthly injectable risperidone in the ATRIGEL delivery system for the treatment of schizophrenia. The FDA has set a PDUFA target actio
12/12/17 - Injectable Drug Delivery Devices Market by Devices and Formulation, Etc. Types and Foresight to 2023
Injectable drug delivery devices Market provide a detailed analysis, mainly based on Value Chain analysis, Porter's Five Forces, Price analysis, and Supply Chain analysis etc. Becton Dickinson and Company, Baxter International, Schott AG, Eli Lilly and Company, Pfizer, Gerresheimer AG, Terumo Corporation, Antares Pharma Inc., Novo Nordik, Sanofi SA
12/12/17 - New Data for DARZALEX (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple
Janssen Research& Development, LLC today announced new data from the Phase 1 b PAVO clinical study, which demonstrated that the subcutaneous delivery of DARZALEX (R) had a manageable safety profile and a 12 percent rate of infusion reactions in patients with relapsed or refractory multiple myeloma.1 These data were featured as an oral presentation
12/12/17 - Orexo Discloses More Information About the Improved Market Access Position for Zubsolv US in 2018
Orexo AB today announces specific information about the improved market access position for Zubsolv sublingual tablet in the US effective January 1, 2018, and previously announced in the Interim Report for the third quarter of 2017. Recently, the Formulary List of Covered Drugs for 2018 has been announced by all managed care programs, thus enabling
12/12/17 - Patch Fentanyl Transdermal Patch Fen Touch 50 Mcg [TendersInfo (India)]
Tenders are invited for Patch fentanyl transdermal patch fen touch 50 mcg. Type: Limited Major organization: CENTRAL RAILWAY Address: MEDICAL Country: India Tender notice number: CRS181918720068 Notice type: Tender Notice Open date: 2017-11-22. Tender documents: T429675006.html, 429675006. pdf.
12/12/17 - Phase 1 Data for Flotetuzumab, MacroGenics CD123 x CD3 DART Molecule, Presented at 59th Annual ASH Meeting [T-break Tech (Middle East)]
MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced the presentation of clinical data from its ongoing Phase 1 study of flotetuzumab in an oral...
12/12/17 - Phase III IMmotion151 study showed Roche's Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer
Basel- Phase III IMmotion151 study showed Roche's Tecentriq and Avastin reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer. *Data will be discussed with health authorities globally, including the US Food and Drug Administration and European Medicines Agency. Roche today announced t
12/12/17 - Pump may beat shots for Type 1 diabetes [Qatar Tribune]
"Insulin pumps work, and they work even somewhat better than multiple daily injections overall," said Icahn School of Medicine, Mount Sinai, New York City, Pediatric Endocrinology Chief Dr Robert Rapaport. Winthrop Hospital in Mineola, NY, Pediatric Endocrinologist Dr Siham Accacha, explained why that might be so. The start-up cost for a pump can b
12/12/17 - Report Summarizes Drug Delivery Systems Study Findings from Bahauddin Zakariya University (Review: Nanopreparations for better drug delivery)
By a News Reporter-Staff News Editor at Cancer Weekly Research findings on Drugs and Therapies- Drug Delivery Systems are discussed in a new report. According to news reporting originating in Multan, Pakistan, by NewsRx editors, the research stated, "Nanomedicines are a recent development to face medical and pharmaceutical challenges because nano
12/12/17 - scPharmaceuticals Inc. to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to transform infused therapies, advance patient care and reduce healthcare costs, today announced that Troy A. Ignelzi, chief financial officer of scPharmaceuticals, will present at the BMO Capital Markets Prescriptions for.
12/12/17 - SIGA Technologies Announces FDA Submission of its New Drug Application for oral TPOXX (tecovirimat) to Treat Smallpox [Tehran Times (Iran)]
SIGA Technologies, Inc., a health security company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced the submission of its New Drug Application to the U.S. Food and Drug Administration for the oral formulation of TPOXX. Phil Gomez, Chief Executive Officer of SIGA Techn
12/12/17 - The Global Special Purpose Needle Market is Envisioned to Register a Notable CAGR of 7.5% over the Forecast Period
BROOKYLN, 11230, UNITED STATES, December 12, 2017/ EINPresswire.com/ Special Purpose Needle Market: Global Demand Analysis& Opportunity Outlook 2023 The global special purpose needle market is segmented into product type such as fine aspirating needles, biopsy needles, hypodermic needles, pen needles, suture needles, IV catheter needles, im
12/11/17 - BioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of Hemophilia (ASH) Meeting
BioMarin Pharmaceutical Inc. announced updates on valoctocogene roxaparvovec, an investigational gene therapy treatment for severe hemophilia at ASH. Please see full release issued December 9, 2017 here for details. "The confluence of new medicines and advanced treatment approaches for hemophilia has created an unprecedented opportunity to impro
12/11/17 - BioVie Receives FDA Fast Track Designation for BIV201 for the Treatment of Refractory Ascites Due to Advanced Liver Cirrhosis
BioVie Inc., a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, announced today that the US Food and Drug Administration has granted Fast Track designation for BIV201, the Company's patented Orphan drug candidate. "We appreciate the FDA's recognition of the importance of develo
12/11/17 - Cardiome Announces Xydalba Treatment And Patient Experience Presentations At The 2017 National Opat Conference
-Cardiome Pharma Corp., a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced a plenary sponsored symposium at the 2017 National Outpatient Parenteral Antimicrobial Therapy Conference, hosted by the British Society for Antimicrobial Chemotherapy, taking place December...
12/11/17 - Cardiome Announces Xydalba? Treatment And Patient Experience Presentations At The 2017 National Opat Conference
-Cardiome Pharma Corp., a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced a plenary sponsored symposium at the 2017 National Outpatient Parenteral Antimicrobial Therapy Conference, hosted by the British Society for Antimicrobial Chemotherapy, taking place December...
12/11/17 - FDA Approves Ferring's CLENPIQ sodium picosulfate, magnesium oxide, and anhydrous citric acid Oral Solution for Colonoscopy Prep
By a News Reporter-Staff News Editor at Pharma Business Week The U.S. Food and Drug Administration has granted Ferring Pharmaceuticals Inc. approval to market CLENPIQ? oral solution for cleansing of the colon in adults undergoing a colonoscopy. Edward Brettholz, Clinical Assistant Professor of Medicine, NYU School of Medicine. Keywords for this
12/11/17 - Findings from Thomas Jefferson University Update Understanding of Proinsulin (Detailed Analysis of Insulin Absorption Variability and the Tissue...
By a News Reporter-Staff News Editor at Diabetes Week Researchers detail new data in Peptide Proteins- Proinsulin. According to news reporting out of Philadelphia, Pennsylvania, by NewsRx editors, research stated, "Worldwide, approximate to 1 million people manage their type 1 diabetes with an insulin pump and a continuous subcutaneous insulin in
12/11/17 - Fortress Biotech Announces Positive Clinical Data From Fortress Companies Presented at the 59th American Society of Hematology Annual Meeting
Fortress Biotech, Inc., a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced positive clinical data on therapies under development at its Fortress Company subsidiaries Caelum Biosciences, Inc., and Mustang Bio, Inc., were presented in oral sessions at t
Articles(s): 1 - 25 of 131     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415